A61K 40/4243
Wilms tumor 1 [wt1]
Official title: {Wilms tumor 1 [WT1]}
A61K40/4243 (Wilms tumor 1 [wt1]) appears on 123 US grants and 235 published applications in this corpus.
Search patents in A61K- Granted patents
- 123
- Published applications
- 235
- Assignees
- 100
- Inventors
- 349
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 7 |
| 2004 | 0 | 2 |
| 2005 | 0 | 2 |
| 2006 | 3 | 2 |
| 2007 | 0 | 2 |
| 2008 | 3 | 2 |
| 2009 | 4 | 3 |
| 2010 | 2 | 7 |
| 2011 | 3 | 5 |
| 2012 | 1 | 2 |
| 2013 | 2 | 3 |
| 2014 | 4 | 11 |
| 2015 | 7 | 9 |
| 2016 | 6 | 13 |
| 2017 | 6 | 10 |
| 2018 | 8 | 15 |
| 2019 | 7 | 21 |
| 2020 | 8 | 15 |
| 2021 | 11 | 19 |
| 2022 | 11 | 23 |
| 2023 | 9 | 24 |
| 2024 | 5 | 13 |
| 2025 | 15 | 14 |
| 2026 | 8 | 11 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptors to HER2 and methods of use thereof22 Sep 2026US 12,742,020 B2BioAtla, Inc.
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- T-cell immunotherapy specific for WT-116 Jun 2026US 12,653,886 B2Fred Hutchinson Cancer Center
- Determining WT-1-specific T cells and WT-1 specific T cell receptors (TCRS)2 Jun 2026US 12,644,154 B2Adaptive Biotechnologies Corporation
- Targeted T-cell therapy for treatment of multiple myeloma31 Mar 2026US 12,590,292 B2Children's National Medical Center
- Compositions including anti-wt-1 antibodies & antigen binding fragments and uses thereof6 Aug 2026US 2026/0226173 A1
- Immune cell organoid co-cultures23 Jul 2026US 2026/0210940 A1HUB Organoids IP B.V.
- Polynucleotides, polypeptides, cells, and compositions comprising synthetic immune receptors with methods of manufacture and treatment18 Jun 2026US 2026/0167693 A1Angeles Therapeutics, Inc.
- Anti-wt1/hla antibodies and uses thereof4 Jun 2026US 2026/0152571 A1Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Method for inducing t cells for immunotherapy from pluripotent stem cells4 Jun 2026US 2026/0152726 A1Kyoto University
Most cited
By later US patents
- Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases143US 8,956,828 B2Ospedale San Raffaele S.R.L. · 2015
- Tumor antigen based on products of the tumor suppressor gene WT145US 7,030,212 B1Haruo Sugiyama · 2006
- Targeted disruption of T cell receptor genes using talens38US 9,937,207 B2Ospedale San Raffaele S.R.L. · 2018
- Tumor antigen based on products of the tumor suppressor gene WT132US 7,608,685 B1International Institute of Cancer Immunology, Inc. · 2009
- Compositions and methods for WT1 specific immunotherapy27US 7,144,581 B2Corixa Corporation · 2006